[go: up one dir, main page]

MX2013001468A - Nueva sintesis para compuestos de tiazolidindiona - Google Patents

Nueva sintesis para compuestos de tiazolidindiona

Info

Publication number
MX2013001468A
MX2013001468A MX2013001468A MX2013001468A MX2013001468A MX 2013001468 A MX2013001468 A MX 2013001468A MX 2013001468 A MX2013001468 A MX 2013001468A MX 2013001468 A MX2013001468 A MX 2013001468A MX 2013001468 A MX2013001468 A MX 2013001468A
Authority
MX
Mexico
Prior art keywords
novel synthesis
thiazolidinedione compounds
compounds
thiazolidinedione
pparî3
Prior art date
Application number
MX2013001468A
Other languages
English (en)
Other versions
MX349006B (es
Inventor
Robert C Gadwood
Steven P Tanis
James R Zeller
Timothy Parker
Gerald D Artman Iii
Original Assignee
Metabolic Solutions Dev Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Solutions Dev Co Llc filed Critical Metabolic Solutions Dev Co Llc
Publication of MX2013001468A publication Critical patent/MX2013001468A/es
Publication of MX349006B publication Critical patent/MX349006B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/141—Esters of phosphorous acids
    • C07F9/145—Esters of phosphorous acids with hydroxyaryl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención proporciona los nuevos métodos para sintetizar compuestos que prescinden de PPAR?, por ejemplo, las tiazolidindionas, que son útiles para prevenir y/o tratar trastornos metabólicos tales como la diabetes, obesidad, hipertensión y trastornos inflamatorios
MX2013001468A 2010-08-10 2011-08-09 Nueva sintesis para compuestos de tiazolidindiona. MX349006B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37228210P 2010-08-10 2010-08-10
PCT/US2011/047010 WO2012021476A1 (en) 2010-08-10 2011-08-09 Novel synthesis for thiazolidinedione compounds

Publications (2)

Publication Number Publication Date
MX2013001468A true MX2013001468A (es) 2013-05-14
MX349006B MX349006B (es) 2017-07-06

Family

ID=44511576

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001468A MX349006B (es) 2010-08-10 2011-08-09 Nueva sintesis para compuestos de tiazolidindiona.

Country Status (15)

Country Link
US (1) US8933240B2 (es)
EP (1) EP2603498B1 (es)
JP (1) JP5927190B2 (es)
KR (2) KR101988203B1 (es)
CN (1) CN103180304B (es)
AU (1) AU2011289543C1 (es)
CA (1) CA2807662C (es)
DK (1) DK2603498T3 (es)
ES (1) ES2609837T3 (es)
HU (1) HUE031424T2 (es)
MX (1) MX349006B (es)
NZ (1) NZ606574A (es)
PL (1) PL2603498T3 (es)
RU (1) RU2593370C2 (es)
WO (1) WO2012021476A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2560956B1 (en) 2010-04-19 2016-10-26 Octeta Therapeutics, LLC Novel synthesis for thiazolidinedione compounds
NZ606597A (en) 2010-08-10 2014-12-24 Metabolic Solutions Dev Co Llc Synthesis for thiazolidinedione compounds

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
SU1766260A3 (ru) * 1989-11-04 1992-09-30 Пфайзер Инк (Фирма) Способ получени производных тиазолидиндиона-2,4 или их фармацевтически приемлемых солей с щелочными металлами
US5102904A (en) * 1989-12-08 1992-04-07 American Cyanamid Company N-oxygenated arylpyrrole insecticidal, acaricidal and nematicidal agents and use thereas
US5143930A (en) 1990-02-07 1992-09-01 Sankyo Company, Limited Thiazolidine derivatives with anti-diabetic activity, their preparation and their use
KR100249988B1 (ko) 1991-04-11 2000-04-01 로렌스 티. 마이젠헬더 티아졸리딘디온 유도체, 그의 제조방법 및 용도
NO302471B1 (no) 1991-12-26 1998-03-09 Sankyo Co Tiazolidinforbindelser og farmasöytisk preparat
DE4304861A1 (en) * 1992-02-20 1993-08-26 Ciba Geigy Ag Microbicidal compsns., esp. fungicides for plant protection - contg. new or known 2-amino-2-phenyl-ethyl-phosphonic acid cpds.
SE9702305D0 (sv) 1997-06-17 1997-06-17 Astra Ab New thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives
JPH1171358A (ja) * 1997-06-20 1999-03-16 Sankyo Co Ltd ５−ベンジルチアゾリジン−２，４−ジオン誘導体の製法
AP869A (en) 1998-01-05 2000-09-04 Pfizer 2,3-Substituted indole compounds as anti-inflammatory and analgesic agents.
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US6768008B2 (en) 2000-04-24 2004-07-27 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
CA2430924A1 (en) 2000-12-01 2002-06-06 Novartis Ag Angiotensin receptor antagonist composition for the treatment of sexual dysfunction associated with hypertension and another condition
WO2003029251A1 (en) 2001-09-28 2003-04-10 Biocon Limited Novel process for the synthesis of thiazolidinedione derivatives
JP2004300367A (ja) * 2003-04-01 2004-10-28 Toyo Ink Mfg Co Ltd 光重合開始剤組成物
FR2861069B1 (fr) 2003-10-17 2005-12-09 Galderma Res & Dev NOUVEAUX LIGANDS ACTIVATEURS DES RECEPTEURS RARs, UTILISATION EN MEDECINE HUMAINE AINSI QU'EN COSMETIQUE
JP2008527043A (ja) * 2005-01-19 2008-07-24 ブリストル−マイヤーズ スクイブ カンパニー 血栓塞栓障害治療用のｐ２ｙ１受容体阻害剤としての２−フェノキシ−ｎ−（１，３，４−チアジアゾール−２−イル）ピリジン−３−アミン誘導体および関連化合物
CN101454005B (zh) 2006-03-16 2013-01-02 新陈代谢解决方案开发公司 用于治疗代谢性炎症介导的疾病的噻唑烷二酮类似物
EP2001469B1 (en) 2006-03-16 2012-05-23 Metabolic Solutions Development Company LLC Thiazolidinedione analogues
US8435983B2 (en) 2007-03-23 2013-05-07 The University Of Toledo Conformationally restrained epothilone analogues as anti-leukemic agents
PL2203433T3 (pl) * 2007-09-14 2013-04-30 Metabolic Solutions Dev Co Llc 5-(4-(2-(3-metoksyfenylo)-2-oksoetoksy)benzylo)tiazolidyno-2,4-dion do stosowania w leczeniu cukrzycy
WO2009148195A1 (en) 2008-06-02 2009-12-10 Daebong Ls, Ltd. 5-(4-hydroxybenzyl)thiazolidine-2,4-dione as intermediate for synthesis of thiazolidinedione based compounds and process for preparing the same
WO2010105048A1 (en) * 2009-03-12 2010-09-16 Metabolic Solutions Development Company Thiazolidinedione analogues
EP2560956B1 (en) * 2010-04-19 2016-10-26 Octeta Therapeutics, LLC Novel synthesis for thiazolidinedione compounds
WO2011133441A2 (en) 2010-04-19 2011-10-27 Metabolic Solutions Development Company Novel synthesis for thiazolidinedione compounds
NZ606597A (en) * 2010-08-10 2014-12-24 Metabolic Solutions Dev Co Llc Synthesis for thiazolidinedione compounds

Also Published As

Publication number Publication date
KR20190018027A (ko) 2019-02-20
RU2013110310A (ru) 2014-09-20
CN103180304B (zh) 2017-02-15
EP2603498B1 (en) 2016-11-09
US8933240B2 (en) 2015-01-13
DK2603498T3 (en) 2017-01-16
KR20130099034A (ko) 2013-09-05
AU2011289543B2 (en) 2015-03-19
JP2013535504A (ja) 2013-09-12
ES2609837T3 (es) 2017-04-24
AU2011289543C1 (en) 2019-05-23
KR101988203B1 (ko) 2019-06-11
AU2011289543A1 (en) 2013-02-21
PL2603498T3 (pl) 2017-06-30
CN103180304A (zh) 2013-06-26
HUE031424T2 (en) 2017-07-28
WO2012021476A1 (en) 2012-02-16
CA2807662A1 (en) 2012-02-16
US20130204008A1 (en) 2013-08-08
NZ606574A (en) 2015-02-27
JP5927190B2 (ja) 2016-06-01
CA2807662C (en) 2019-10-08
EP2603498A1 (en) 2013-06-19
MX349006B (es) 2017-07-06
RU2593370C2 (ru) 2016-08-10

Similar Documents

Publication Publication Date Title
MX2012012094A (es) Sintesis novedosa para compuestos de tiazolidinadiona.
MX351368B (es) Compuestos heteroarilo y metodos para utilizarlos.
HRP20130357T1 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases.
CY1118187T1 (el) Χημικες ενωσεις
IN2012DN03883A (es)
MY160468A (en) Novel amino azaheterocyclic carboxamides
MY153915A (en) Organic compounds
UA115136C2 (uk) Заміщені 4-фенілпіридини для лікування хвороб, пов'язаних з рецептором nk-1
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
EA201171063A1 (ru) Фармацевтические составы олмесартана
EA201070256A1 (ru) Способ и промежуточные соединения для получения ингибиторов интегразы
MY186456A (en) Quinazoline carboxamide azetidines
ZA201005116B (en) 6.7-dialkoxy ouinazoline derivatives useful for treatment of cancer related disorders
PH12013501757A1 (en) Asymmetric ureas and medicals uses thereof
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
MX2012012092A (es) Sintesis novedosa para compuestos de tiazolidinadiona.
WO2012082862A3 (en) Androgen receptor inhibitors and methods of use thereof
NZ702239A (en) Heteroaryl compounds and methods of use thereof
MX2010006331A (es) Hidantoinas sustituidas como inhibidores de cinasa mek.
MX2014003883A (es) Inhibidores de monoacilglicerol lipasa para el tratamiento de enfermedades metabolicas y transtornos relacionados.
MX2013001475A (es) Sintesis para compuestos de tiazolidindiona.
WO2010148177A3 (en) Compounds, compositions, methods of synthesis, and methods of treatment
MX2013001468A (es) Nueva sintesis para compuestos de tiazolidindiona
WO2009126335A3 (en) Ant2 inhibitor compounds and methods of use thereof
PH12012502137A1 (en) Pyrimidinyl indole compounds

Legal Events

Date Code Title Description
GB Transfer or assignment

Owner name: OCTETA THERAPEUTICS, LLC

FG Grant or registration